Related Experiment Video
Updated: Sep 21, 2026

A Platform of Anti-biofilm Assays Suited to the Exploration of Natural Compound Libraries
Published on: December 27, 2016
In-vitro pharmacodynamic studies of piperacillin/tazobactam with gentamicin and ciprofloxacin
1Department of Medical Microbiology, Aberdeen Royal Hospital NHS Trust, Aberdeen Royal Infirmary, UK.
Abstract:
Six isolates each of Enterococcus faecium, Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pyogenes, Stenotrophomonas maltophilia, Pseudomonas aeruginosa, Citrobacter spp., Serratia spp., Acinetobacter spp. and Enterobacter spp. (total 60 strains) were studied against the combination of piperacillin/tazobactam plus gentamicin or ciprofloxacin at physiological concentrations by the microtitre chequerboard method incorporating simultaneous time-kill curves. Tazobactam was fixed at 4 mg/L. Gentamicin plus piperacillin/tazobactam was a synergic combination against 28 strains at 2 h, 51 at 5 h and 54 at 24 h as assessed by time-kill curves and synergic or additive (FBC index < or = 1) against all 60 strains at 24 h by chequerboards. The corresponding figures for ciprofloxacin plus piperacillin/tazobactam were seven, 26, 52 and 58 respectively. Antagonism (FBC index > or = 4) was demonstrated for one strain to each combination at 24 h. There were no significant differences between FIC indices and FBC indices for each antibiotic combination. Gentamicin plus piperacillin/tazobactam gave > or = 3 log kill for 47 strains by 2 h, 56 by 5 h and 59 by 24 h. Ciprofloxacin plus piperacillin/tazobactam gave > or = 3 log kill for 22 strains by 2 h, 36 by 5 h and 56 by 24 h. In conclusion both antibiotic combinations at physiological concentrations were synergic or additive at 24 h for the majority of strains tested although notably gentamicin plus piperacillin/tazobactam gave faster kill. Antagonism was rarely seen. Both combinations are likely to prove beneficial for treatment of serious infections.
Insights
Gentamicin plus piperacillin/tazobactam demonstrated faster bacterial kill than ciprofloxacin plus piperacillin/tazobactam. Both antibiotic combinations showed synergy or additive effects against most tested strains, indicating potential benefits for serious infections.
Area of Science:
- Microbiology
- Pharmacology
- Infectious Diseases
Background:
- Antibiotic resistance is a growing global health concern.
- Piperacillin/tazobactam is a broad-spectrum antibiotic combination.
- Gentamicin and ciprofloxacin are commonly used antibiotics.
Purpose of the Study:
- To evaluate the synergistic effects of piperacillin/tazobactam combined with gentamicin or ciprofloxacin.
- To compare the efficacy of these combinations against various bacterial pathogens.
- To assess the speed of bacterial kill by these antibiotic combinations.
Main Methods:
- Microtitre chequerboard method to determine fractional inhibitory concentration (FIC) indices.
- Time-kill curves to assess synergistic activity and bacterial kill rates.
- Testing against 60 clinical isolates including Gram-positive and Gram-negative bacteria.
Main Results:
- Gentamicin plus piperacillin/tazobactam showed synergistic or additive effects against all 60 strains at 24 hours, with faster kill rates observed at 2 and 5 hours.
- Ciprofloxacin plus piperacillin/tazobactam also demonstrated synergistic or additive effects against most strains at 24 hours.
- Antagonism was rarely observed for either combination.
Conclusions:
- Both antibiotic combinations are effective and likely beneficial for treating serious bacterial infections.
- Gentamicin plus piperacillin/tazobactam exhibits a more rapid bactericidal effect compared to ciprofloxacin combination.
- The tested combinations show promise in combating challenging bacterial pathogens.
More Related Videos
11:17Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses
Published on: August 30, 2018
09:26Antibiotic Efficacy Testing in an Ex vivo Model of Pseudomonas aeruginosa and Staphylococcus aureus Biofilms in the Cystic Fibrosis Lung
Published on: January 22, 2021
Related Concept Videos
Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations
Pharmacodynamic Models: Overview